Servier Group is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Servier’s focus is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. As an affiliate of the Servier Group, Servier Canada works assiduously to provide the Canadian medical community and its patients with innovative therapeutic solutions. Servier Canada partners with various stakeholders in the life science ecosystem including researchers, academic partners, clinicians, patient associations, and innovators. In addition to these partners, the International Center for Therapeutic Research (ICTR) located in Laval, is dedicated to preclinical and clinical development, with more than 50 studies conducted throughout Canada over the last 10 years. In 2022, Servier Canada has been recognized for its commitment to innovation in the annual ranking of Canada's Top 100 Research and Development (R&D) spenders.
More information: www.servier.ca